Compare BridgeBio Pharma Inc (BBIO) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares Global Clean Energy ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while iShares Global Clean Energy ETF trades at $18.22. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | ICLN | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $23.75 |
52-Week Low | $47.29 | $13.66 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
ICLN trades at $18.30, up 0.99% today, but technical indicators signal a bearish trend with resistance near $19. The ETF lacks key valuation metrics like P/E and P/S due to its structure, and recent news highlights competition from traditional energy ETFs offering higher yields and lower fees. Clean energy faces policy risks, with stalled U.S. permits threatening investment, though global demand for renewables remains strong.
Outlook is cautious; ICLN offers growth exposure to 105 global clean energy firms but underperforms peers on fees and dividends. Risks include regulatory uncertainty and volatility, while analyst sentiment is mixed amid sector comparisons. Investors should weigh long-term green energy trends against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
